Get started
Author

Silvia Cornejo‐Uixeda

Observed names: S. Cornejo‐Uixeda, Silvia Cornejo-Uixeda
ORCID: 0000-0002-6678-5440
Observed ORCID: 0000-0002-6678-5440
OpenAlex ID: A5082985379
Patient preference after switching guselkumab from prefilled syringe to an autoinjection pen in psoriasis and psoriatic arthritis patients
2024 · Joaquin Borrás-Blasco, Rebeca Alcalá García, et al. · Farmacia Hospitalaria · 4
Pancreatitis inducida por capecitabina
2017 · Silvia Cornejo-Uixeda, Corina Escoin-Pérez, et al. · Medicina Clínica · 4
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn’s Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)
2025 · Joaquin Borras-Blasco, Alejandro Valcuende-Rosique, et al. · The American Journal of Gastroenterology · 2
Economic impact of a faricimab vial‐sharing protocol in age‐related macular degeneration and diabetic macular oedema patients
2025 · J. Borrás‐Blasco, J. Abad, et al. · Acta Ophthalmologica · 2
PDF
Letter to the editor on “Effectiveness, safety and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV ‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study”
2025 · Joaquín Borrás‐Blasco, Alejandro Valcuende‐Rosique, et al. · HIV Medicine · 1
Letter to the editor regarding “efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study”
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · International Immunopharmacology · 1
Comment on ‘Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years’
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Clinical and Experimental Dermatology · 1
Real-World Persistence on Tofacitinib in Psoriatic Arthritis Patients With Enthesitis: Comments on Recent Findings
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · The Journal of Rheumatology · 1
PDF
Regarding “Effectiveness and Persistence of Anti-TNFα Treatment in Patients with Rheumatoid Arthritis - A 7 Years Real-World Cohort Study” [Letter]
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Biologics · 1
PDF
[Artículo traducido] Preferencia del paciente tras cambiar guselkumab de jeringa precargada a pluma autoinyectable en pacientes con psoriasis y artritis psoriásica
2024 · Joaquin Borrás-Blasco, Rebeca Alcalá García, et al. · Farmacia Hospitalaria · 1
Letter to the editor regarding ‘Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan’
2026 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Remission and treatment persistence during sequential therapy in rheumatoid arthritis: results from the Estonian Biologic Treatment Registry
2026 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Rheumatology International
Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis
2026 · Joaquin Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · World Journal of Dermatology
PDF
Comments on “Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study”
2026 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Intestinal Research
PDF
Letter to the editor ‘high persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study)’
2026 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Scandinavian Journal of Gastroenterology
Comment on: Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety
2026 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Therapeutic Advances in Gastroenterology
Letter to the Editor Regarding ‘National and Regional Drug Survival of Omalizumab in Chronic Spontaneous Urticaria: A Danish Cohort Study’
2026 · Joaquín Borrás‐Blasco, Alejandro Valcuende‐Rosique, et al. · Clinical & Experimental Allergy
Letter to the Editor “Use and Persistence of Beta 3‐Adrenoceptor Agonists for the Treatment of Overactive Bladder”
2026 · Joaquín Borrás‐Blasco, Alejandro Valcuende‐Rosique, et al. · International Journal of Urology
Correspondence on ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry’ by Hernández-Cruz et al.
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Annals of the Rheumatic Diseases
Letter to the Editor Regarding “Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study”
2025 · Joaquín Borras-Blasco, Alejandro Valcuende-Rosique, et al. · Journal of Psoriasis and Psoriatic Arthritis
Letter to the Editor Regarding “Treatment Persistence Among Anti–Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent”
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Clinical Therapeutics
PDF
Letter to the Editor “Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy”
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Journal of Diabetes and its Complications
Letter to the Editor Regarding “Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis”
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Inflammatory Bowel Diseases
Letter to the editor regarding “Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort”
2025 · Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical
Capecitabine induced pancreatitis
2018 · Silvia Cornejo-Uixeda, Corina Escoin-Pérez, et al. · Medicina Clínica (English Edition)
Works count: 27
Citation count: 18
H-index: 2
I10-index:
Year
Topic
Type